Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Documenti analoghi

• Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
  di: Santagostino, Elena, et al.
  Pubblicazione: (2016)
• Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
  di: Kenet, Gili, et al.
  Pubblicazione: (2016)
• Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs
  di: Nolte, M. W., et al.
  Pubblicazione: (2012)
• Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
  di: Astermark, Jan, et al.
  Pubblicazione: (2021)
• Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
  di: Mancuso, Maria Elisa, et al.
  Pubblicazione: (2020)